Search
forLearn
5 / 801 resultslearn octapeptide-2
learn enoxolone
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Research
5 / 1000+ results
research PRX102 Participates in Root Hairs Tip Growth of Rice
PRX102 is essential for rice root hair growth by helping transport substances to the tips.
research Identification of potential key genes and pathways associated with the Pashmina fiber initiation using RNA-Seq and integrated bioinformatics analysis
Key genes and pathways, including Wnt, NF-Kappa, and JAK-STAT, are crucial for starting Pashmina fiber growth in goats.
research Gingerol ameliorates chronic graft-versus-host disease by regulating treg/Th17 transdifferenciation
Gingerol may help treat chronic graft-versus-host disease by improving immune cell balance.
research Fibroblasts and wound healing: an update
Understanding different types of skin cells, especially fibroblasts, can lead to better treatments for wound healing and less scarring.
research The antiandrogenic effect of finasteride against a mutant androgen receptor
Finasteride may improve prostate cancer treatment outcomes.
Community Join
5 / 1000+ resultscommunity carriers other than PG for ru58841 ? Help !!
community Setipiprant/PGE2 feedbacks?
community For everyone buying 2-deoxy-d-ribose (2ddr)
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community RU58841 powder from lab supplier tested at free drug testing service.
Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.